Page 1068 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 15

435. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth 450. Walsh TJ, et al. A randomized, double-blind, multicenter trial
PA. Prolonged granulocytopenia: the major risk factor for inva- of caspofungin versus liposomal amphotericin B for empirical
sive pulmonary aspergillosis in patients with acute leukemia. antifungal therapy of persistently febrile neutropenic patients.
Ann Intern Med. 1984;100:345-351. 43rd International Conference on Antimicrobial Agents and
436. Alberti C, Bouakline A, Ribaud P, et al. Relationship between Chemotherapy; 2003; Chicago, IL.
environmental fungal contamination and the incidence of 451. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid
invasive aspergillosis in haematology patients. J Hosp Infect. complex for invasive fungal infections: analysis of safety and
2001;48(3):198-206. efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383-1396.
437. Pagano L, Caira M, Candoni A, et al. invasive aspergillosis in 452. Linden P, Williams P, Chan KM. Efficacy and safety of ampho-
patients with acute myeloid leukemia: SEIFEM-2008 registry tericin B lipid complex injection (ABLC) in solid-organ
study. Haematologica. October 22, 2010;95:644-650. transplant recipients with invasive fungal infections. Clin
438. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Transplant. 2000;14(4, pt 1):329-339.
Multivariate analysis of factors associated with invasive fungal 453. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid com-
disease during remission induction therapy for acute myelog- plex in pediatric patients with invasive fungal infections. Pediatr
enous leukemia. Cancer. 1984;53:411-419. Infect Dis J. 1999;18(8):702-708.
439. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease 454. Wingard JR, Kubilis P, Lee L, et al. Clinical significance
in pediatric acute leukemia patients with fever and neutropenia of nephrotoxicity in patients treated with amphotericin
during induction chemotherapy: a multivariate analysis of risk B for suspected or proven aspergillosis. Clin Infect Dis.
factors. J Clin Oncol. 1990;8(2):280-286. 1999;29:1402-1407.
440. Tollemar J, Ringden O, Bostrom L, Nilsson B, Sundberg B. 455. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J,
Variables predicting deep fungal infections in bone mar- Arrieta A. A randomized, double-blind comparative trial evalu-
row transplant recipients. Bone Marrow Transplant. ating the safety of liposomal amphotericin B versus ampho-
1989;4(6):635-641. tericin B lipid complex in the empirical treatment of febrile
441. Jensen HE, Salonen J, Ekfors TO. The use of immunohisto- neutropenia. Clin Infect Dis. 2000;31(5):1155-1163.
chemistry to improve sensitivity and specificity in the diagnosis 456. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic
of systemic mycoses in patients with haematological malignan- analysis of liposomal amphotericin B versus conventional
cies. J Pathol. 1997;181(1):100-105. amphotericin B in the empirical treatment of persistently febrile
442. Pagano L, Caira M, Picardi M, et al. Invasive Aspergillosis in neutropenic patients. J Clin Oncol. 2000;18(12):2476-2483.
patients with acute leukemia: update on morbidity and mortality– 457. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole
SEIFEM-C Report. Clin Infect Dis. 2007;44(11):1524-1525. versus amphotericin B for primary therapy of invasive aspergil-
losis. N Engl J Med. August 8, 2002;347(6):408-415.
443. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients
of hematopoietic stem cell transplants: results of the SEIFEM 458. Cornely OA, Bohme A, Reichert D, et al. Risk factors for break-
B-2004 study–Sorveglianza Epidemiologica Infezioni Fungine through invasive fungal infection during secondary prophy-
Nelle Emopatie Maligne. Clin Infect Dis. 2007;45(9):1161-1170. laxis. J Antimicrob Chemother. April 2008;61(4):939-946.
444. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated 459. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K,
with overall and attributable mortality in invasive aspergillosis. Groll AH. Secondary antifungal prophylaxis in paediatric
Clin Infect Dis. 2008;47(9):1176-1184. allogeneic haematopoietic stem cell recipients. J Antimicrob
Chemother. March 2008;61(3):734-742.
445. Walsh T, Anaissie E, Denning D, et al. Treatment of Aspergillosis:
Clinical Practice Guidelines of the Infectious Diseases Society 460. Grigg A, Slavin M. Minimizing the risk of recurrent or progres-
of America. Clin Infect Dis. 2008;46(3):327-360. sive invasive mold infections during stem cell transplantation
or further intensive chemotherapy. Transpl Infect Dis. February
446. Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A,
Cordonnier C. Treatment of invasive Candida and invasive 2008;10(1):3-12.
Aspergillus infections in adult haematological patients. EJC 461. Robertson MJ, Larson RA. Recurrent fungal pneumonias
Suppl. 2007;5(2):49-59. in patients with acute nonlymphocytic leukemia undergo-
ing multiple courses of intensive chemotherapy. Am J Med.
447. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive
fungal infections in cancer patients—recommendations of the 1988;84(2):233-239.
Infectious Diseases Working Party (AGIHO) of the German 462. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treat-
Society of Hematology and Oncology (DGHO). Ann Hematol. ment of invasive fungal diseases in allogeneic stem cell trans-
February 2009;88(2):97-110. plantation: results of a consensus process by Gruppo Italiano
Trapianto di Midollo Osseo (GITMO). Clin Infect Dis. October
448. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, 15 2009;49(8):1226-1236.
double-blind study of combination antifungal therapy with
voriconazole and anidulafungin versus voriconazole monother- 463. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for
apy for primary treatment of invasive aspergillosis. Abstracts secondary prophylaxis of invasive fungal infections in alloge-
of the 22nd European Congress of Clinical Microbiology and neic stem cell transplant recipients: results of the VOSIFI study.
Infectious Diseases. Vol 18. London, United Kingdom: European Haematologica. October 2010;95(10):1762-1768.
Society for Clinical Microbiology and Infectious Diseases; 464. Greene JN. Catheter-related complications of cancer therapy.
2012:713. Infect Dis Clin North Am. 1996;10(2):255-295.
449. Maertens J, Boogaerts M. Caspofungin in the treatment of 465. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the
candidosis and aspergillosis. Int J Infect Dis. 2003;7(2):94-101. prevention of intravascular catheter-related infections. Centers

Section05-O-ref.indd 15 1/20/2015 4:51:21 PM